| Home > Institute Collections > W500 > NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. |
| Journal Article | DKFZ-2025-02468 |
; ; ; ; ; ; ; ; ; ;
2022
Molecular Diversity Preservation International
Basel
Abstract: Lung cancer cells in the tumor microenvironment facilitate immune evasion that leads to failure of conventional chemotherapies, despite provisionally decided on the genetic diagnosis of patients in a clinical setup. The current study follows three lung cancer patients who underwent 'personalized' chemotherapeutic intervention. Patient-derived xenografts (PDXs) were subjected to tumor microarray and treatment screening with chemotherapies, either individually or in combination with the peptide R11-NLS-pep8; this peptide targets both membrane-associated and nuclear PCNA. Ex vivo, employing PDX-derived explants, it was found that combination with R11-NLS-pep8 stimulated antineoplastic effect of chemotherapies that were, although predicted based on the patient's genetic mutation, inactive on their own. Furthermore, treatment in vivo of PDX-bearing mice showed an exactly similar trend in the result, corroborating the finding to be translated into clinical setup.
Keyword(s): Humans (MeSH) ; Mice (MeSH) ; Animals (MeSH) ; Drug Delivery Systems (MeSH) ; Peptides: pharmacology (MeSH) ; Antineoplastic Agents: pharmacology (MeSH) ; Antineoplastic Agents: therapeutic use (MeSH) ; Lung Neoplasms: drug therapy (MeSH) ; Tumor Microenvironment (MeSH) ; Disease Models, Animal (MeSH) ; NKp44 ; PCNA-binding peptide ; lung cancer ; personalized medicine ; synergistic effect ; tumor xenograft ; Peptides ; Antineoplastic Agents
|
The record appears in these collections: |